Tracking the evolution of non-small-cell lung cancer

New England Journal of Medicine

Volumn 376, Issue 22, 2017, Pages 2109-2121

  Jamal Hanjani, Mariam ^a,e   Wilson, Gareth A ^a,d   McGranahan, Nicholas ^a,d   Birkbak, Nicolai J ^a,d   Watkins, Thomas B K ^d   Veeriah, Selvaraju ^a   Shafi, Seema ^a   Johnson, Diana H ^a   Mitter, Richard ^e   Rosenthal, Rachel ^a   Salm, Max ^e   Horswell, Stuart ^e   Escudero, Mickael ^e   Matthews, Nik ^f   Rowan, Andrew ^d   Chambers, Tim ^d   Moore, David A ^l   Turajlic, Samra ^d,h   Xu, Hang ^d   Lee, Siow Ming ^a,e   Forster, Martin D ^a,e   Ahmad, Tanya ^e   Hiley, Crispin T ^d   Abbosh, Christopher ^a,e   Falzon, Mary ^e   Borg, Elaine ^e   Marafioti, Teresa ^e   Lawrence, David ^e   Hayward, Martin ^e   Kolvekar, Shyam ^e   Panagiotopoulos, Nikolaos ^e   Janes, Sam M ^a,b,e   Thakrar, Ricky ^e   Ahmed, Asia ^e   Blackhall, Fiona ^o,p   Summers, Yvonne ^p   Shah, Rajesh ^e   Joseph, Leena ^e   Quinn, Anne M ^e   Crosbie, Phil A ^e   Naidu, Babu ^e   Middleton, Gary ^s   Langman, Gerald ^e   Trotter, Simon ^e   Nicolson, Marianne ^t   Remmen, Hardy ^t   Kerr, Keith ^t   Chetty, Mahendran ^t   Gomersall, Lesley ^t   Fennell, Dean A ^l   Nakas, Apostolos ^m   Rathinam, Sridhar ^m   Anand, Girija ⁱ   Khan, Sajid ^j,u   Russell, Peter ^v   Ezhil, Veni ^w   Ismail, Babikir ^x   Irvin Sellers, Melanie ^x   Prakash, Vineet ^x   Lester, Jason F ^y   Kornaszewska, Malgorzata ^aa   Attanoos, Richard ^aa,ab   Adams, Haydn ^z   Davies, Helen ^z   Dentro, Stefan ^g,ac,ad   Taniere, Philippe ^r   O'Sullivan, Brendan ^r   Lowe, Helen L ^b   Hartley, John A ^b   Iles, Natasha ^k   Bell, Harriet ^k   Ngai, Yenting ^k   Shaw, Jacqui A ^l   Herrero, Javier ^b   Szallasi, Zoltan ^ae,af,ag   Schwarz, Roland F ^ah   Stewart, Aengus ^e   Quezada, Sergio A ^c   Le Quesne, John ^l,n   Van Loo, Peter ^g,ai   Dive, Caroline ^a,q   Hackshaw, Allan ^k   Swanton, Charles ^a,d,e,h   more..

^a University of Manchester and University College London   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Cancer Immunology Unit   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Translational Cancer Therapeutics Laboratory ^*  (United Kingdom)

^f Advanced Sequencing Facility   (United Kingdom)

^g Cancer Genomics Laboratory   (United Kingdom)

^h THE FRANCIS CRICK INSTITUTE   (United Kingdom)

ⁱ NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m GLENFIELD HOSPITAL   (United Kingdom)

ⁿ Medical Research Center Toxicology Unit   (United Kingdom)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p CHRISTIE HOSPITAL   (United Kingdom)

^q MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^r BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^s UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^t UNIVERSITY OF ABERDEEN   (United Kingdom)

^u ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^v PRINCESS ALEXANDRA HOSPITAL   (United Kingdom)

^w St Lukes Surgery   (United Kingdom)

^x ASHFORD AND ST PETER'S HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^y VELINDRE CANCER CENTRE   (United Kingdom)

^z LLANDOUGH HOSPITAL   (United Kingdom)

^aa CARDIFF UNIVERSITY   (United Kingdom)

^ab UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^ac WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^ad UNIVERSITY OF OXFORD   (United Kingdom)

^ae TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^af HARVARD MEDICAL SCHOOL   (United States)

^ag SEMMELWEIS UNIVERSITY   (Hungary)

^ah MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^ai UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BCL11A GENE; BRAF GENE; CDK4 GENE; CHROMOSOMAL INSTABILITY; CLONAL VARIATION; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DEATH; DNA DAMAGE; DNA REPAIR; EGFR GENE; FOXA1 GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MET GENE; MOLECULAR EVOLUTION; NF1 GE; NON SMALL CELL LUNG CANCER; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SQUAMOUS CELL LUNG CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WHOLE GENOME SEQUENCING; DISEASE FREE SURVIVAL; DNA SEQUENCE; EXOME; FEMALE; GENETIC HETEROGENEITY; GENETICS; LUNG TUMOR; MALE; MORTALITY; MUTATION; PHYLOGENY; PROCEDURES; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMAL INSTABILITY; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; EVOLUTION, MOLECULAR; EXOME; FEMALE; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHYLOGENY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 85019668203     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1616288     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
5. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
6. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150: 1121-34.
7. Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016; 48: 607-16.
8. de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251-6.
9. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256-9.
10. Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol 2014; 12(7): e1001906.
11. Alexandrov LB, Nik-Zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun 2015; 6: 8683.
12. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
13. Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. Nat Genet 2015; 47: 1402-7.
14. Roberts SA, Lawrence MS, Klimczak LJ, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45: 970-6.
15. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-21.
16. Dewhurst SM, McGranahan N, Burrell RA, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 2014; 4: 175-85.
17. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437: 1043-7.
18. Martincorena I, Roshan A, Gerstung M, et al. Tumor evolution: high burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348: 880-6.
19. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
20. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
21. Middleton G, Crack LR, Popat S, et al. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol 2015; 26: 2464-9.
22. Abrams J, Conley B, Mooney M, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book 2014; : 71-6.
23. Greaves M. Evolutionary determinants of cancer. Cancer Discov 2015; 5: 806-20.
24. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
25. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
26. Cao Y, Xiao G, Qiu X, Ye S, Lin T. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One 2014; 9(12): e114008.
27. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 2012; 13: 528-38.
28. Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013; 110: 21083-8.